Imunon, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Imunon, Inc. (IMNN) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $195.54 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-11
- Imunon, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $99.00K, a 10.41% increase year-over-year.
- Imunon, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $96.54K, a 26.44% decline year-over-year.
- Imunon, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $94.19K, a 26.44% decline year-over-year.
- Imunon, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $91.89K, a 26.45% decline year-over-year.
- Imunon, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $406.99K, a 14.84% decline from fiscal 2024.
- Imunon, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $477.94K, a 1.29% increase from fiscal 2023.
- Imunon, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $471.85K, a 11.82% decline from fiscal 2022.
- Imunon, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $535.12K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $99.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $195.54K 10-Q · filed 2026-08-11 | $289.73K derived: sum of 3 quarters · filed 2026-08-11 | $381.62K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $96.54K 10-Q · filed 2026-05-12 | $190.73K derived: sum of 2 quarters · filed 2026-05-12 | $282.63K derived: sum of 3 quarters · filed 2026-05-12 | $372.29K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $94.19K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $186.08K derived: sum of 2 quarters · filed 2026-03-31 | $275.75K derived: sum of 3 quarters · filed 2026-08-11 | $406.99K 10-K · filed 2026-03-31 |
| 2025-09-30 | $91.89K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $181.56K derived: sum of 2 quarters · filed 2026-08-11 | $312.81K 10-Q · filed 2025-11-13 | $440.85K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $89.67K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $220.91K 10-Q · filed 2026-08-11 | $348.96K derived: sum of 3 quarters · filed 2026-08-11 | $473.90K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $131.25K 10-Q · filed 2026-05-12 | $259.30K derived: sum of 2 quarters · filed 2026-05-12 | $384.24K derived: sum of 3 quarters · filed 2026-05-12 | $501.18K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $128.05K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $252.99K derived: sum of 2 quarters · filed 2026-03-31 | $369.93K derived: sum of 3 quarters · filed 2026-03-31 | $477.94K 10-K · filed 2026-03-31 |
| 2024-09-30 | $124.94K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $241.88K derived: sum of 2 quarters · filed 2025-11-13 | $349.89K 10-Q · filed 2025-11-13 | $418.80K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $116.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $224.95K 10-Q · filed 2025-08-05 | $293.86K derived: sum of 3 quarters · filed 2025-08-05 | $424.12K derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $108.01K 10-Q · filed 2025-05-12 | $176.92K derived: sum of 2 quarters · filed 2025-05-12 | $307.19K derived: sum of 3 quarters · filed 2025-05-12 | $436.70K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $68.91K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $199.18K derived: sum of 2 quarters · filed 2025-02-27 | $328.69K derived: sum of 3 quarters · filed 2025-02-27 | $471.85K 10-K · filed 2025-02-27 |
| 2023-09-30 | $130.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $259.78K derived: sum of 2 quarters · filed 2024-11-07 | $402.94K 10-Q · filed 2024-11-07 | $541.88K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $129.51K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $272.68K 10-Q · filed 2024-08-14 | $411.61K derived: sum of 3 quarters · filed 2024-08-14 | $547.21K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $143.16K 10-Q · filed 2024-05-13 | $282.10K derived: sum of 2 quarters · filed 2024-05-13 | $417.70K derived: sum of 3 quarters · filed 2024-05-13 | |
| 2022-12-31 | $138.94K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $274.54K derived: sum of 2 quarters · filed 2024-03-28 | $535.12K 10-K · filed 2024-03-28 | |
| 2022-09-30 | $135.60K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $396.18K 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $260.58K 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |